The crystal study:: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri

被引：0
|
作者：
Van Cutsem, E. [1 ]
Lang, I [2 ]
D'haens, G. [3 ]
Moiseyenko, V [4 ]
Zaluski, J. [5 ]
Koehne, C. [6 ]
Folprecht, G. [7 ]
Tejpar, S. [1 ]
Shparyk, Y. [8 ]
Schlichting, M. [9 ]
Kisker, O. [9 ]
Stroh, C. [9 ]
Rougier, P. [10 ]
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Orszagos Onkol Intezet, Budapest, Hungary
[3] Imelda Ziekenhuis, Bonheiden, Belgium
[4] NN Petrov Oncol Res Inst, St Petersburg, Russia
[5] Weikopolskie Centrum Onkol, Poznan, Poland
[6] Klinikum Oldenburg, Oldenburg, Germany
[7] Univ Klin Carl Gustav Carus, Dresden, Germany
[8] Lviv Oncol Med & Diagnost Ctr, Lvov, Ukraine
[9] Merck Serono, Darmstadt, Germany
[10] Hop Ambroise Pare, Boulogne, France
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：17 / 18
页数：2
相关论文
共 50 条
  • [41] The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study
    Hsiang-Lin Tsai
    Chun-Chi Lin
    Yung-Chung Sung
    Shang-Hung Chen
    Li-Tzong Chen
    Jeng-Kai Jiang
    Jaw-Yuan Wang
    British Journal of Cancer, 2023, 129 : 947 - 955
  • [42] Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients
    Stintzing, S.
    Jung, A.
    Rossius, L.
    Modest, D. P.
    von Weikersthal, L. Fischer
    Decker, T.
    Moehler, M.
    Scheithauer, W.
    Kirchner, T.
    Heinemann, V.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S8 - S9
  • [43] Quality of life analysis in patients with RAS wild-type metastatic colorectal cancer treated with first-line FOLFIRI plus cetuximab in the CRYSTAL study
    Yamaguchi, K.
    Ando, M.
    Ooki, A.
    Beier, F.
    Guenther, S.
    Von Hohnhorst, P.
    Van Cutsem, E.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S370 - S371
  • [44] KRAS MUTATIONS AND OUTCOME IN PATIENTS WITH METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE CHEMOTHERAPY WITH OR WITHOUT CETUXIMAB
    Tejpar, Sabine
    Bokemeyer, Carsten
    Celik, Ilhan
    Schlichting, Michael
    Heeger, Steffen
    Van Cutsem, Eric
    ANNALS OF ONCOLOGY, 2011, 22 : v16 - v17
  • [45] A randomized, open-label cecog phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab and FOLFIRI plus cetuximab as first-line therapy in metastatic colorectal cancer (MCRC)
    Ciuleanu, T.
    Scheithauer, W.
    Kurteva, G.
    Ocvirk, J.
    Koza, I
    Papamichael, D.
    Vrbanec, D.
    Brodowicz, T.
    Beslija, S.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [46] Randomized phase II study of duligotuzumab plus FOLFIRI versus cetuximab plus FOLFIRI in 2nd-line patients with KRAS wild-type (wt) metastatic colorectal cancer (mCRC)
    Hill, Andrew G.
    Findlay, Michael
    Burge, Matthew
    Jackson, Christopher
    Garcia Alfonso, Pilar
    Samuel, Leslie
    Ganju, Vinod
    Karthaus, Meinolf
    Amatu, Alessio
    Jeffery, Mark
    DiBartolomeo, Maria
    Bridgewater, John
    Coveler, Andrew
    Hidalgo, Manuel
    Kapp, Amy V.
    Sufan, Roxana
    McCall, Bruce
    Penuel, Elicia
    Pirzkall, Andrea
    Tabernero, Josep
    CANCER RESEARCH, 2015, 75
  • [47] CETUXIMAB PLUS XELIRI VERSUS CETUXIMAB PLUS XELOX AS FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): ANALYSIS OF THE RANDOMIZED TRIAL OF THE GERMAN AIO CRC STUDY GROUP: KRK-0204
    Stintzing, S.
    Jung, A.
    Vehling-Kaiser, U.
    Stauch, M.
    Hass, H.
    Dietzfelbinger, H.
    von Weikersthal, L. Fischer
    Moosmann, N.
    Kirchner, T.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2010, 21 : 189 - 190
  • [48] Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306
    Pietrantonio, F.
    Garassino, M. C.
    Torri, V.
    de Braud, F.
    ANNALS OF ONCOLOGY, 2012, 23 (10) : 2771 - 2772
  • [49] Genetic variations within the HER3 gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab or FOLFIRI/cetuximab: Data from FIRE-3
    Berger, M. D.
    Stintzing, S.
    Heinemann, V.
    Cao, S.
    Yang, D.
    Miyamoto, Y.
    Suenaga, M.
    Hanna, D. L.
    Soni, S.
    Puccini, A.
    Tokunaga, R.
    Naseem, M.
    Battaglin, F.
    McSkane, M.
    Zhang, W.
    Lenz, H-J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [50] ANALYSIS OF MOLECULAR ALTERATIONS FOR PREDICTING CLINICAL BENEFIT TO CETUXIMAB PLUS CHEMOTHERAPY IN FIRST-LINE METASTATIC COLORECTAL CANCER (MCRC)
    Javier, Sastre
    Patricia, Llovet
    Julian, Sanz
    Inmaculada, Bando
    Milagros, Ferrer
    Alfonso Pilar, Garcia
    Olga, Donnay
    Alfredo, Carrato
    Ana, Jimenez-Gordo
    Enrique, Aranda
    Ana, Leon
    Cristina, Gravalos
    Juan Carlos, Camara
    Jaime, Feliu
    Beatriz, Sanchiz
    Trinidad, Caldes
    Eduardo, Diaz-Rubio
    ANNALS OF ONCOLOGY, 2014, 25
12345